By Colin Kellaher
Zevra Therapeutics shares fell sharply on Monday after the U.S. Food and Drug Administration extended its review of the rare disease company’s lead drug candidate arimoclomol.
Shares of the Celebration, Fla., company were recently down nearly 13% to $6.19.
Zevra, which is seeking approval of arimoclomol for the rare neurodegenerative disorder Niemann-Pick disease type C, said the FDA moved its target action date to Sept. 21 from June 21 after the company provided additional analyses at the agency’s request.
Zevra said it remains confident in arimoclomol’s potential, and that it will continue to work closely with the FDA as the agency completes its review.
Write to Colin Kellaher at colin.kellaher@wsj.com
Read the full article here
